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Infektiotaudit ovat tavallinen ongelma päivystysklinikalla. Erityisesti sepsiksen diagnosointi on hankalaa, 
sillä taudille ei tällä hetkellä ole olemassa sopivaa biomarkkeria. Sepsis on melko yleinen, nopeasti 
etenevä systeeminen infektio, johon liittyy merkittävän suuri kuolleisuus. Jo parissa päivässä oireiden 
alkamisesta kehittyvään vakavaan sepsikseen menehtyy noin 70 % potilaista. Tämän vuoksi varhaisen 
vaiheen diagnostiikka ja nopea, tehokkaan mikrobilääkehoidon aloitus ovat elintärkeitä sepsispotilaille. 
Biomarkkerin puuttumisen vuoksi hoidon aloitus viivästyy ja potilaan ennuste heikkenee. 
Aiemmissa tutkimuksissa on havaittu elimistössä laaja-alaisesti esiintyvän proproteiini konvertaasi 
furiinin yhteys monenlaisiin tulehdustiloihin. Furiini on proteaasientsyymi, joka säätelee muun muassa T 
auttaja 1 -solujen aktiivisuutta sekä TLR7 reseptorien määrää. Lisäksi lipopolysakkaridi (LPS) lisää sen 
ilmentymistä makrofageissa.  
Tutkimuksen tavoitteena on selvittää voitaisiinko päivystyksessä potilaiden plasmanäytteistä mitattuja 
furiinipitoisuuksia käyttää hyväksi infektion varhaisen vaiheen diagnostiikassa, vakavuuden arvioinnissa, 
kuolleisuuden ennustamisessa ja/tai oikeanlaisen antibioottihoidon valitsemisessa. 
Potilasaineisto kerättiin Satakunnan keskussairaalasta vuosina 2004 ja 2005. Se koostuu täysi-ikäisistä, 
päivystyspoliklinikalle saapuneista infektioepäilypotilaista. Verinäytteet kerättiin päivystyksessä ja muu 
data haastattelusta ja sairaskertomuksista. Plasman furiinipitoisuus määritettiin kaupallisella ELISA-
menetelmällä (Human Furin Enzyme Linked Immunosorbent Assay,  Sigma-Aldrich®) ja tulokset jaettiin 
korkean ja matalan pitoisuuden ryhmiin. Myös potilaat jaoteltiin infektiotyypin perusteella viiteen 
diagnostiseen ryhmään. Tilastolliset analyysit suoritettiin SPSS-ohjelmalla (IBM, versio 22).  
Tilastollisesti merkitsevää yhteyttä ei havaittu verrattaessa sepsiksen yleisyyttä (P = 0,421), diagnostista 
ryhmää (P = 0,737) sekä veriviljelyn tulosta (P = 0,351) potilaan furiinitasoon. Furiinipitoisuus ja 
kuolleisuus eivät myöskään liittyneet toisiinsa (P = 0,898). Merkitsevät korrelaatiot löydettiin korkean 
furiinitason ja tupakoimattomuuden (P = 0,034) sekä reumasairauksien (P < 0,001) väliltä.  
Furiini ei sovellu infektiomarkkeriksi päivystyspoliklinikalla eikä sen plasmapitoisuudesta voida tehdä 
johtopäätöksiä liittyen taudin vakavuuteen tai potilaan ennusteeseen. Pitoisuuksien määrittämisestä ei 
myöskään ole apua oikean mikrobilääkkeen valinnassa. Toisaalta, furiinitasojen jakautumista olisi 
jatkossa mielenkiintoista tutkia erityisesti reumapotilaista koostuvassa aineistossa. 
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1. INTRODUCTION 
 
 
Sepsis is a major cause of mortality. In severe sepsis, mortality rises up to 60-70% [1, 2]. Potentially 
fast disease progression is the main reason why early diagnosis and quick adequate treatment are 
extremely important in this condition. Even an hour-long delay in adequate antimicrobial treatment 
may have an adverse impact on prognosis [3, 4]. 
Currently used biomarkers for the diagnosis of sepsis are C-reactive protein (CRP), blood leukocytes, 
and procalcitonine (PCT) [5, 6]. None of these biomarkers are suitable for the early stages of sepsis; 
they can be used for confirmation, but not for exclusion of the diagnosis. For example, CRP levels begin 
to rise only after 12 hours of the early signs of sepsis and it is not a specific marker of bacterial 
infection [7, 8].  
The proprotein convertase subtilisin/kexin enzymes (PCSKs) belong to the subtilisin superfamily of 
serine endoproteases, which convert immature precursor proteins into the biologically functional 
units by catalyzing post-translational site-specific hydrolytic cleavage [9, 10]. FURIN is the first found 
and therefore the most studied mammalian proprotein convertase. This ubiquitously expressed 
enzyme is located mainly in the trans-Golgi network (TGN) of the secretory pathway. In addition, 
FURIN cycles between TGN and the cell surface via the endosomal system, and a proportion of it is 
secreted to the extracellular space [11, 12]. Because FURIN is widely expressed, its activity regulates 
the maturation of numerous precursor proteins. Its substrates include various growth factors and 
their receptors, enzymes, hormones, cytokines, serum proteins, as well as extracellular-matrix 
proteins [10, 11]. In addition to FURIN´s crucial function in the maintenance of cellular homeostasis, it 
is also involved in the pathogenesis of several diseases. For example, increased FURIN levels are 
associated with aggressive cancers and metastatic activity [11], and it is highly expressed in 
chronically inflamed tissues in rheumatoid arthritis (RA) and atherosclerosis [13, 19]. FURIN has also 
a significant role in the activation of viruses and bacterial pro-toxins. These pathogens include bird flu 
(AH5N1), HIV and Ebola viruses as well as the toxins of Bacillus anthracis and Clostridium botulinum 
[12].  
Because FURIN is essential for the embryogenesis, our understanding on its cell-type specific in vivo 
function is incomplete [13]. However, we have previously shown that FURIN is profoundly 
upregulated in T helper type 1 (Th1) cells via the IL-12/Stat4 pathway and by T cell receptor mediated 
signaling [14]. T-cell-expressed FURIN regulates the Th cell polarization and the peripheral immune 
tolerance primarily by controlling the functional maturation of anti-inflammatory cytokine 
transforming growth factor beta (TGFβ-1) [14, 15, 16]. In macrophages the expression and secretion of 
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FURIN is induced by lipopolysaccharide (LPS) [17, 18], and a FURIN-like enzyme controls the quantity 
and activation of the human Toll-like receptor 7 (TLR7) [20]. In contrast, relatively little is known 
about the FURIN levels in human infections, but an elevated serum concentration has been reported in 
chronically Salmonella typhi infected patients [17].  
The fact that FURIN is upregulated upon immune cell activation and its key regulatory role in host 
defence prompted us to evaluate the usability of plasma FURIN as an early stage infection biomarker. 
Specifically, we analyzed whether the proprotein convertase FURIN levels in plasma could be useful in 
predicting the severity and case fatality of infection in a large, randomly selected cohort of patients 
that were admitted the emergency room with suspected infection. 
 
2. METHODS  
2.1. Study population 
 
The study population was recruited in the Satakunta Central Hospital, Finland within a 14-month 
study period in 2004 to 2005 [6, 21, 22, 23]. Satakunta Central Hospital is a secondary care hospital 
with 350-beds serving a population of 240 000 inhabitants. There are no other hospitals with an 
emergency room and an intensive care unit (ICU) in the Satakunta area. All of the involved patients 
were adults, who had been admitted to the emergency room with a suspected infection status and 
been drawn a blood culture sample. The study was approved by the ethical review board of                 
the Satakunta Hospital District. Written consent was obtained from patients or close relatives. To 
ensure written informed consent and interview within 24-48 hours, only patients admitted between 
Sunday   7 a.m. and Wednesday 3 p.m. were enrolled [23]. 
The plasma samples were taken simultaneously with the blood culture samples and collected in two 
10-ml EDTA tubes. The EDTA tubes were kept on ice before the centrifugation in 2500 G-force for     
10-15 minutes. The samples were then transported in 1 to 2 ml aliquots to CryoPure®               
(Sartsedt, Germany) tubes and further stored at  -70 °C [23].  
The information for the statistical analysis was obtained from an interview held by a researcher or        
a research nurse within 24-48 hours after the admission. Highest body temperature, lowest blood 
pressure, highest pulse and the respiratory rate were measured daily during the first week of 
hospitalization. In addition, symptoms and clinical signs, Glasgow coma scale, risk factors for sepsis, 
underlying disease, diagnosis at admission, prospective organ failure (cardiovascular, hematological, 
hepatic, renal, respiratory or central nervous system), universal case fatality and the case fatality 
caused by sepsis were documented in ICU and in the ward. Other information such as the potential 
reason and the cause of the infection and trauma together with the final diagnose were checked from 
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patient´s medical records. Follow-up surveys were conducted by phone 3 months and one year after 
patient´s admission. Before initiating the study, a pre-evaluation of the target population was 
conducted to ensure the representativeness of the cohort. This assessment covered 1551 consecutive 
patients from whom blood had been collected in the emergency department for blood culture. The rate 
of positive blood culture in the pre-evaluation was 8.3% and case fatality by day 28 after admission 
was 6.7%. No significant differences in age, gender, rate of positive blood culture or mortality were 
noted between patients admitted on study days and those admitted on other days, or between the 
study and the pre-evaluation populations. [23] 
In total, blood samples were taken from 609 patients. 55 samples were removed because of the 
patient´s reluctance to participate in the research, and 17 samples were left out from other reasons:     
1 missing, 11 unclear results, 3 with SIRS and multi-organ failure but no bacterial infection and               
2 samples ran out. As a result, the final cohort comprised of 537 patients [23]. 
 
2.2. Measurement of plasma FURIN levels 
 
The concentration of proprotein convertase FURIN was determined from EDTA plasma samples using 
a commercial Human FURIN Enzyme-Linked Immunosorbent Assay (ELISA) Kit (Sigma-Aldrich®, 
USA) according to manufacturer´s instructions. The reliable detection limit of the assay was 
determined to be 370 pg/ml, and the concentrations below that were considered as low/absent. In 
general, all samples were analyzed once, but analysis was replicated with a higher dilution for the 
samples showing exceptionally high FURIN levels. The patients were stratified into low and high 
plasma FURIN groups with a cut-off at 370 pg/ml. 
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2.3. Statistical analysis 
 
The detected FURIN concentrations were transferred to the SPSS Statistics for Windows software 
(IBM, version 22) for statistical analyses. The study population was divided into five diagnosis groups 
based on The American Collage of Chest Physicians/Society of Critical Care Medicine Consensus 
Conference definitions of the severity of the infection stage. [24]. 
Nonparametric independent-samples t-test for Independent Samples or Analysis of Variance were 
used with normally distributed variables, and Mann-Whitney U-Test or Kruskal-Wallis test for the rest. 
Two binomial variables were analyzed with Chi-Square or Fishers exact test. Linear and Logistic 
Regression were used to examine the effect of potential confounders. The Kaplan-Meier and the Log-
rank test were used to investigate the connection between the FURIN levels and the case fatality.  
The common significance levels were used to determine the importance of the outcomes: P <0.05 
illustrated a statistically significant result, and P <0.001 was considered as a statistically highly 
significant discovery. 
 
3. RESULTS  
 
 
The demographic data of the study population (n = 537), underlying diseases as well as the infection-
associated clinical parameters during the first 28 days are presented in Table 1. The plasma FURIN 
levels were measured from all samples as described in methods. The assay standard curve was 
prepared using serial dilutions of recombinant FURIN protein, and a reliable linearity was detected 
only with FURIN levels above 370 pg/ml, which was thus determined as cut-off for high FURIN levels 
in plasma. The cohort was stratified into five study groups on the basis of ACCP/SCCM Consensus 
Conference definitions (Table 2) [24], and further divided into low and high FURIN samples. In the five 
different groups high FURIN levels were detected in 14.9% - 22.0% of samples, with lowest percentage 
of high FURIN samples in Bacterial infection, no SIRS group (Group 2), and highest in no SIRS, no 
bacterial infection group (Group 1). However, differences in the prevalence of high FURIN levels 
between different groups were not significant (P = 0.737). 
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Table 1 Demographic and clinical characteristics of the study population (N = 537). 
                                 N    Percentage     
Characteristic 
        Age, median (range) 
  
         64.2 (18 - 100) 
     Gender (male) 
  
310       (57.7%) 
    Obesity (BMIa ≥ 30 kg/m2), median (range)          27.0 (14.7 - 67.6) 
    Alcohol abuseb 
  
25       (4.7%) 
    Smoking (current smoker) 
 
126       (23.5%) 
    Diabetes (types 1 and 2) 
 
81       (15.1%) 
    Solid cancer 
  
78       (14.5%) 
    Malignancy (solid or haematological) 95       (17.7%) 
    Rheumatic disease 
  
50       (9.3%) 
    Chronic renal insufficiencyc 
 
18       (3.4%) 
    Cardiovascular diseased 
 
289       (53.8%) 
    Continuous cortisone treatmente 
 
59            (11.0%) 
  
        Clinical parameters (d 0-28) 
       Case fatality (d 28) 
  
33       (6.1%) 
    Case fatality (d 90) 
  
58       (10.8%) 
    Case fatality (1 year) 
  
112       (20.9%) 
    ICUf stay needed 
  
42       (7.8%) 
    Hypotensiong 
  
28       (5.2%) 
    DICh 
   
8       (1.5%) 
    Decreased GCSi 
  
60       (11.2%) 
    Mechanical ventilation 
 
14       (2.6%) 
    C-PAP/bi-PAPj 
  
22       (4.1%) 
    Sepsis + organ dysfunction  
 
49       (9.1%) 
    MOFk 
   
10      (1.9%) 
  
 
              
Demographics are reported as a number and percentage except age and obesity which are 
reported as median and range. 
aBody mass index, data available on 390 patients. 
   bAlcoholism was diagnosed or patient had previously been treated for alcohol-induced disease. 
cPlasma creatinine concentration continually more than 170 µmol L-1 (five patients underwent 
chronic dialysis treatment). 
dContinuous medication for cardiovascular disease (including hypertension and arteriosclerosis). 
eContinuous systemic cortisone treatment (daily dose > 10 mg oral prednisolone). 
 fIntensive care unit. 
      gSystolic blood pressure < 90 mmHg or a reduction of 40 mmHg from baseline. No response to 500
mL intravenous fluid replacement. 
hDisseminated intravascular coagulation. 
    iGlasgow coma scale < 15. 
     jContinuous positive airway pressure/ bilevel positive airway pressure. 
  kMulti-organ failure. 
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Table 2 The distribution of emergency room patients stratified by diagnosis group into low or high FURIN levels. 
      
 
                    
         
FURIN < 370 pg/ml 
 
FURIN ≥ 370 pg/ml 
         (N = 429)  (N = 108) 
Diagnosis group   Criteria           n percentage   n percentage 
1. No SIRS, no bacterial infection  Patients with no SIRSa  
    
46 (78.0%) 
 
13 (22.0%) 
    (N = 59) 
  
(less than two SIRS criteria +/- 24 hours) 
      
   
or documentedb or probablec bacterial infection 
       2. Bacterial infection, no SIRS Patients with documental or        57 (85.1%)   10 (14.9%) 
    (N = 67)     probable bacterial infection, but no SIRS     
  
  
        (less than two SIRS criteria +/- 24 hours)   
  
  
  3. SIRS, no bacterial infection Patients with SIRS ( at least two SIRS criteria +/- 24 hours), 
 
45 (83.3%) 
 
9 (16.7%) 
    (N = 54) 
  
but no documental or probable bacterial infection 
       
              4. Sepsis     Patients with sepsis ( SIRS and documented      242 (78.6%)   66 (21.4%) 
    (N = 308)     or probable bacterial infection but no dysfunction      
  
  
        due to sepsis)         
  
  
  5. Severe sepsis  
 
Patients with severe sepsis (sepsis with signs of organ 
 
39 (79.6%) 
 
10 (20.4%) 
    (N = 49) 
  
failure, i.e. distrubted perfusion, metabolic acidosis,  
            oliguria or neurological disorders)                 
Differences between five groups were studied using the Chi-Square test (P = 0.737). 
       aSystemic inflammatory response syndrome (SIRS): at least two of the following conditions. 1. Temperature > 38°C or < 36°C; 2. Heart rate >90 beats 
    per min; 3. Respiratory rate > 20 breaths per min or partial pressure of carbon dioxide in arterial blood [PaCO2] < 32 mmHg (4.3 kPA). 
     4. White blood cell count > 12 x 109 L-1 or > 10% immature (band) forms). 
        bDocumented bacterial infection: microbiologically confirmed bacterial infection (either pathogenic bacterial growth in blood culture or in  
     normally sterile tissue or the same usually less pathogenic bacterium, for example, Staphylococcus epidermidis, in two different samples). 
   cProbable bacterial infection: a clinician suspected bacterial infection and either infection focus was confirmed or antimicrobial treatment was started 
 and the response to treatment supported bacterial infection. 
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We next assessed if high FURIN level in plasma associated with patients’ demographic characteristics 
or infection-associated clinical parameters (Table 3). Although elevated FURIN levels have been found 
in malignancies and atherosclerosis [11, 13, 25], there were no statistically significant associations 
with high FURIN plasma levels and the prevalence of solid cancer (P = 0.606) or cardiovascular 
diseases       (P = 0.204). However, in keeping with the elevated FURIN expression in inflamed tissues 
in RA [19], FURIN plasma concentrations over 370 pg/ml associated highly significantly with a 
diagnosed rheumatic disease. Specifically, only 7.0% of the patients in the group with lower levels of 
FURIN were suffering from rheumatic diseases in contrast to 18.5% in the high FURIN level group (P < 
0.001). The plasma level of FURIN was over 370 pg/ml in 40% of arthritis patients compared to only 
18 % in the cohort without rheumatic disease (data not shown). Interestingly, albeit tobacco smoking 
places a burden on the immune system, and could thus be envisioned to increase FURIN expression 
through the immune cell activation, we also found a significant association between current smokers 
and low FURIN plasma levels (P = 0.034).  
In contrast, during the first 28 days FURIN plasma levels did not significantly associate with any of the 
investigated clinical parameters including multi-organ failure (P = 0.421) or the occurrence of sepsis     
(P = 0.957); also there was no statistically significant connection to a 28-day case fatality when 
examining patients with sepsis as a direct cause of dead or a contributing factor on patients decease     
(P = 0.463). In conclusion, the current data imply that assessing FURIN plasma levels does not have 
value as a diagnostic marker for patients with a suspected infection. 
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Table 3. The distribution of patients’ demographic characteristics and clinical parameters into the two FURIN levels (N = 537). 
 
   
FURIN < 370 pg/ml  (N = 429) 
 
FURIN ≥ 370 pg/ml  (N = 108) 
        N   Percentage   N   Percentage   P-value 
Characteristic 
          Age, median (range) 
 
     63.82 (18 - 100) 
 
            66.38 (20 - 94) 
 
0.618 
  Gender (male) 
 
246      (57.35%) 
 
64       (59.3%) 
 
0.719 
  Obesity (BMIa ≥ 30 kg/m2), median (range)     27.20 (14.7 - 62.5) 
 
         26.67 (15.1 - 67.6) 
 
0.320 
  Alcohol abuseb 
 
22      (5.1%) 
 
3        (2.8%) 
 
0.300 
  Smoking (current smoker) 109      (25.4%) 
 
17        (15.7%) 
 
0.034 
  Diabetes (types 1 and 2) 
 
68      (15.9%) 
 
13        (12.0%) 
 
0.322 
  Solid cancer 
 
64      (14.9%) 
 
14        (13.0%) 
 
0.606 
  Malignancy (solid or haematological) 79      (18.4%) 
 
16        (14.8%) 
 
0.381 
  Rheumatic disease 
 
30       (7.0%) 
 
20        (18.5%) 
 
<0.001 
  Chronic renal insufficiencyc 16       (3.7%) 
 
2         (1.9%) 
 
0.333 
  Cardiovascular diseased 
 
225      (52.4%) 
 
64        (59.3%) 
 
0.204 
  Continuous cortisone treatmente 42       (9.8%) 
 
17        (15.7%) 
 
0.077 
          Clinical parameters (d 0-28) 
         Case fatality (d 28) 
 
28       (6.5%) 
 
5         (4.6%) 
 
0.463 
  Case fatality (d 90) 
 
49      (11.4%) 
 
9         (8.3%) 
 
0.355 
  Case fatality (1 year) 
 
90      (21.0%) 
 
22        (20.4%) 
 
0.889 
  ICUf stay needed 
 
30       (7.0%) 
 
12        (11.1%) 
 
0.154 
  Hypotensiong 
 
23       (5.4%) 
 
5         (4.6%) 
 
0.760 
  DICh 
  
7       (1.6%) 
 
1         (0.9%) 
 
0.588 
  Decreased GCSi 
 
50      (12.2%) 
 
10         (9.6%) 
 
0.460 
  Mechanical ventilation 
 
11       (2.6%) 
 
3         (2.8%) 
 
0.901 
  C-PAP/bi-PAPj 
 
16       (3.7%) 
 
6         (5.6%) 
 
0.392 
  Sepsis + organ dysfunction  39       (9.1%) 
 
10         (9.3%) 
 
0.957 
  MOFk     9       (2.1%)   1         (0.9%)   0.421 
Demographics are reported as a number and percentage in the particular concentration of FURIN 
  Except age and obesity which are reported as median and range. 
     aBody mass index, data available on 390 patients. 
      bAlcoholism was diagnosed or patient had previously been treated for alcohol-induced disease. 
  cPlasma creatinine concentration continually more than 170 µmol L-1 (five patients underwent  chronic dialysis treatment). 
dContinuous medication for cardiovascular disease (including hypertension and arteriosclerosis). 
  eContinuous systemic cortisone treatment (daily dose > 10 mg oral prednisolone). 
   fInstesive care unit. 
        gSystolic blood pressure < 90 mmHg or a reduction of 40 mmHg from baseline.   
 No response to 500 mL intravenous fluid replacement. 
hDisseminated intravascular coagulation. 
       iGlasgow coma scale < 15. 
       jContinuous positive airway pressure/ bi-level positive airway pressure. 
     kMulti-organ failure. 
 
        
 
 9 
To investigate whether FURIN plasma levels could associate with the gram staining results of the 
blood culture samples, we divided the study population into four groups with the alternatives of no 
growth, gram-positive, gram-negative and mixed infection (Table 4); no significant differences in 
FURIN levels were observed (P = 0.351). To explore the more accurate distribution of various bacterial 
species into the two FURIN plasma levels the blood culture results were further divided into the gram-
positive and gram-negative bacterial species (Table 5). Gram-negative Escherichia coli (n = 11) and 
gram-positive Streptococcus pneumoniae (n = 10) were noticeably the most common causes of a 
systemic bacterial infection among our study cohort.  However, the findings again indicated that 
FURIN plasma levels measured simultaneously with the blood culture sampling is not informative 
considering the bacterial strain causing the infection. 
 
Table 4 The distribution of the Gram-staining of bacteria in blood culture findings into the FURIN levels. 
         
   
FURIN < 370 pg/ml  (N = 429) 
 
                  FURIN ≥ 370 pg/ml  (N = 108) 
 Blood culture finding   N Percentage   N Percentage 
No growth 
  
389 (80.2%) 
 
96 (19.8%) 
(N = 485) 
       Gram-positive   20 (71.4%)   8 (28.6%) 
(N = 28)               
Gram-negative 
 
12 (75.0%) 
 
4 (25.0%) 
(N = 16) 
       Mixed      7 (100.0%)   0 (0.0%) 
(N = 7)               
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Table 5 The distribution of different bacterial species measured from blood cultures into two FURIN levels    
 
         
   
FURIN < 370 pg/ml  
 
FURIN ≥ 370 pg/ml  
                     N                N Total    
Gram-positive bacteria 
         Stafylococcus aureus               3               1 4   
  Other Stafylococcus 
  
          2 
  
          2 4 
   Streptococcus pneumoniae             8               2 10   
  Other Streptococcus 
  
          4 
  
          1 5 
   Listeria monocytogenes             0               1 1   
  Anaerobic gram-positive   
bacteria/bacills 
 
          2 
  
          1 3 
 
          Gram-negative bacteria 
         Escherichia coli               9               2 11   
  Pseudomonas 
  
          1 
  
          0 1 
   Other Enterobacterium *             3               0 3   
  Neisseria meningitidis 
 
          0 
  
          1 1 
   Klebsiella                 4               1 5   
  Anaerobic gram-negative 
bacteria/bacills 
 
          1 
  
          0 1 
                     
Differences between values in the table were studied using the Chi-Square test (P = 0.499). 
  * Salmonella, Morganella, Proteus, Pantotea 
       
 
To estimate the potential use of FURIN as a marker for a patient’s prognosis in predicting the severity 
and the case fatality, we constructed two survival curves. First, we examined the overall case fatality 
during the one-year study period (Figure 1). The plasma level of FURIN failed to prognosticate the case 
fatality of an infection in a one-year lasting follow-up period (P = 0.742).  Finally, we wanted to clarify 
the possible prognostic value of FURIN concentrations especially among the patients who had been 
diagnosed with sepsis at the emergency room. According to the fact that basically all of the sepsis-
related deaths occur in the first four weeks since the symptoms had started, we limited the follow-up 
time into 28 days. The cases where sepsis was not a direct cause of dead or did not contribute to 
patient’s decease were censored (n = 13) from the analysis (Figure 2). The statistical significance was 
not found between the survival probability of septic patients and FURIN concentration level                   
(P = 0.898).   
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Figure 1. The survival curve measuring the correlation between low (N = 429) and high (N = 108) 
FURIN levels and the case fatality among the entire study population explored during the one-year 
follow-up (P = 0.742). 
 
 
 
 
 
Figure 2. The survival curve measuring correlation between low (N = 429) and high (N = 108) FURIN 
levels and the case fatality among the patients with the septic infection explored during the 28-day 
follow-up (P = 0.898). Deaths for which the sepsis found in the emergency room did not influence or 
was not the direct the expiration, are censored from the curve (N = 13). 
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4. DISCUSSION  
 
 
We examined the usability of the ubiquitously expressed proprotein convertase FURIN as an 
infection biomarker by determining its plasma concentrations in the study cohort of 537 patients 
admitted to the emergency room with a suspected infection. The present results revealed that FURIN 
cannot be used as a diagnostic biomarker at the emergency room in the early phase of an infection, 
even though it has earlier been associated with various inflammatory conditions [12, 13, 14, 16, 17, 
18, 20]. There were also no statistically significant associations between the FURIN plasma levels and 
the gram staining or the bacterial species of the blood cultures. The concentration of FURIN neither 
associated with the case fatality or the severity of the infection in our study cohort. In contrast, we 
found that patients with a rheumatic disease and patients that were not currently smokers had 
significantly more frequently high plasma concentrations of FURIN. 
The strong association of the elevated plasma FURIN in patients with a rheumatic disease is 
consistent with the earlier findings showing upregulated FURIN in the inflamed joints of RA patients 
[19]. The role of FURIN in autoimmune diseases is not fully understood, but its expression in T cells 
is critical for the functional maturation of pro-TGF-β1 and adequate function of CD4+Foxp3+                
T regulatory cell dependent immune tolerance [16]. Moreover, administration of the recombinant 
FURIN alleviates the inflammation in an experimental collagen-induced arthritis (CIA) mouse model 
[19]. Theoretically elevated FURIN levels in plasma could thus reflect an attempt to harness overly 
active host defense by the activation of anti-inflammatory responses. However, as T-cell-expressed 
FURIN also inhibits Th2 responses and promotes Th1-type inflammation further studies are clearly 
required to fully understand the immunoregulatory role of FURIN in plasma [15]. In any case our 
current finding calls for a further assessment of the value of plasma FURIN levels as a biomarker in 
autoimmune diseases.  
A statistically significant association was also found between the FURIN concentrations below         
370 pg/ml and the habit of smoking. This is somewhat counterintuitive as smoking is generally 
regarded to evoke a chronic inflammatory state in the body involving the expansion in the quantity 
of proinflammatory cytokines [26]. One possible explanation could be that tobacco-related 
substances in plasma interfere with the FURIN measurement, and thus falsify the data. Therefore, 
analyzing FURIN mRNA or protein expression directly in the lungs could give more reliable data on 
the effect of smoking on FURIN levels.   
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To our knowledge, this was the first study assessing the usefulness of proprotein convertase FURIN 
as a diagnostic biomarker for the infections. The strengths of our study were a randomly selected and 
comprehensive study cohort, a high quality of information collection and the follow-up together with 
the broad data on patients’ demographic and clinical characteristics. The wide data including the 
information starting from the underlying diseases and medications as well as received treatment 
during the hospital stay and rehabilitation occurred within one year study time, allowed us to 
undergo multifarious statistical analysis. The information bias and random error were minimized by 
taking the plasma samples for the study simultaneously with the samples taken for the diagnostic 
tests and defining the exact timing for the interviews. This reduced the potential occurrence of both 
the selection and the information bias making the presented results largely generalizable to the 
infectious patients in the Finnish population.   
The sensitivity of the FURIN ELISA kit did not allow measurement of low FURIN concentrations, but 
forced us to stratify the samples into low and high FURIN groups. The transformation of the variable 
from scale to ordinal caused a loss of information and moreover led to the reduction of a statistical 
power of our data. In addition to us, also other research teams have reported the sensitivity of FURIN 
antibody assays as problematic [27]. A more sensitive method for the determination of proprotein 
convertases in plasma could be a direct measurement of the FURIN´s activity using a fluorogenic 
substrate [28]. The downside is that the concerned technique does not distinguish PCSK enzymes 
from each other.  
To determine the FURIN plasma levels in a healthy population we performed a small-scale pilot 
study with six healthy volunteers (data not shown). All these samples showed FURIN levels below 
the cut-off used in this study, but a larger cohort and a more sensitive measurement technique is 
clearly needed to obtain reliable information on the range of normal plasma FURIN.  This may also 
result in reinterpretation of the current data; if the starting levels of FURIN in healthy individuals are 
highly variable the potential rise during the infection would have remained unnoticed even if it 
occurred consistently with every patient. Also, due to lack of sensitivity of the used ELISA kit it 
cannot be excluded that infection-associated changes below 370 pg/ml may have a diagnostic value.  
In conclusion, we have shown that plasma FURIN levels assessed with the current method can not be 
used as a diagnostic biomarker in patients with suspected infection and fail to predict case fatality or 
severity. However, even a low sensitivity ELISA measurement implies that plasma FURIN levels may 
associate with autoimmunity.  
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